Key facts
- SISCAPA Assay Technologies’s last known valuation is $9.5M (Jul 2025).
- It has raised $3.6M across 3 recorded rounds; the latest was Seed Round ($2.0M) in Apr 2025.
- Notable investors include Guo Yu.
- SISCAPA Assay Technologies has filed 3 Form Ds with the SEC since 2012, most recently Aug 2025 ($2.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for SISCAPA Assay Technologies
Funding rounds
3 roundsAbout SISCAPA Assay Technologies
Developer of protein-based technology designed for the adoption of multiplex test panels for clinical use. The company's tools combine antibody-based peptide enrichment with quantitative mass spectrometry to provide accurate quantitation of target proteins, as well as provide analysis using a generic workflow, enabling researchers to understand longitudinal changes in health and disease using simplified sample acquisition methods such as dried blood spots.
- Sector
- Healthcare
- HQ
- Washington, DC, United States
- Founded
- 2011
- Employees
- 11
- Website
- siscapa.com/
- Ownership
- Privately Held (backing)
SISCAPA Assay Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SISCAPA Assay Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SISCAPA Assay Technologies in its N-PORT filings yet. We sweep new filings monthly.